Plasma biomarkers move at different rates across the Alzheimer's disease continuum

Abstract

Background: Alzheimer's disease (AD) is a complex and multifactorial disease, defined by accumulation of Amyloid‐Beta (Aβ) and tau, and ultimately cognitive decline leading to dementia. Plasma biomarkers offer an efficient and non‐invasive method to detect either Aβ or tau pathology but have demonstrated substantially different accuracy.